|
Alias names |
|
B-cell lymphoma protein 2 alpha
|
|
Sequence |
|
MGSSHHHHHH SSGLVPRGSH MAHAGRTGYD NREIVMKYIH YKLSQRGYEW DAGDVGAAPP GAAPAPGIFS SQPGHTPHPA ASRDPVARTS PLQTPAAPGA AAGPALSPVP PVVHLTLRQA GDDFSRRYRR DFAEMSSQLH LTPFTARGRF ATVVEELFRD GVNWGRIVAF FEFGGVMCVE SVNREMSPLV DNIALWMTEY LNRHLHTWIQ DNGGWDAFVE LYGPSMRPLF D
|
|
Concentration |
|
0.5 mg/ml (determined by Bradford assay)
|
|
Substrate/Buffer |
|
Liquid. In 20 mM Tris-HCl buffer (pH8.0) containing 20% glycerol 2 mM DTT
|
|
Storage |
|
Can be stored at +4°C short term (1-2 weeks). For long term storage, aliquot and store at -20°C or -70°C. Avoid repeated freezing and thawing cycles
|
|
References |
|
Zamzami N., et al. (1998) Oncogene. 16(17):2265-82.
Fernandez-Sarabia MJ., et al. (1993) Nature. 366(6452):274-5.
|
|
Contents/Specifications |
|
Recombinant Bcl-2 protein was expressed in E.coli and purified by conventional chromatography, after refolding of the isolated inclusion bodies in a renaturation buffer.
|
|
Notes |
|
Bcl-2, also known as B-cell lymphoma protein 2 alpha, is an anti-apoptotic protein located primarily in the outer mitochondrial membrane that blocks the apoptotic death of some cells such as lymphocytes. BCL-2 is thought to regulate cell death by controlling the mitochondrial membrane permeability during apotosis. Bcl-2 exerts its anti-apoptotic function through inhibiting caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). The Bcl-2 gene has been related with a number of cancers, including melanoma, breast, prostate, and lung carcinomas, as well as schizophrenia and autoimmunity
|